Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KeyCorp (KEY) vs Revvity Inc (RVTY) Price & Performance

KeyCorpTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

KeyCorp vs Revvity Inc — how do they compare? KeyCorp trades at $22.99 (market cap $25.17B), while Revvity Inc trades at $111.26 (market cap $11.87B). The key difference: KeyCorp is far larger — about 2.1× Revvity Inc's market cap, and KeyCorp pays the higher dividend (3.52%). Which is the better fit depends on your goals.

KEYRVTY
Market Cap
$25.17B$11.87B
Sector
FinancialsTechnology
52-Week High
$23.99$117.75
52-Week Low
$16.78$82.26
Dividend Yield
3.52%0.26%
Enterprise Value
$14.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KeyCorp

KeyCorp (KEY) trades at $23.26, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Strong fundamentals include a 26.05% net income margin and 10.61% ROE, while valuation metrics show a P/E of 14.45 and P/B of 1.45. Recent corporate actions include consistent quarterly dividends of $0.21 per share and a new $3 billion buyback program announced in July 2026.

KEY presents a compelling investment case with analyst consensus pointing to significant upside (price target $30.50, 31% potential). The combination of earnings momentum, shareholder-friendly capital returns, and improving loan growth supports bullish sentiment. However, risks include potential pressure on net interest margins from Fed policy and competitive challenges in regional banking. The stock's current valuation appears reasonable relative to earnings growth prospects.

Revvity Inc

RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.

The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About KeyCorp

With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.

Read more on KEY

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY